Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline for smoking cessation in Asian smokers
NCT00141167Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Tobacco Use Disorder (TUD) comparing Varenicline 1 mg BID with Placebo (2 arms). Primary endpoint: 4-week Continuous Quit Rate. Started Feb 2005; status: completed.
02
Drugs
varenicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT00141167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141167.